NEW YORK, Nov. 5, 2013 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a class action lawsuit has been filed in United States District Court for the District of New Jersey, on behalf of all persons who purchased Amarin Corp. plc ("Amrin") (Nasdaq:AMRN) securities during the period July 9, 2009 through October 15, 2013, and who were damaged thereby. This action alleges claims for violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
The Complaint alleges that Defendants misrepresented the prospects for Food and Drug Administration ("FDA") approval of Amarin's Vascepa drug for the ANCHOR indication and failed to disclose that the FDA had informed Amarin that there was a lack of prospective, controlled clinical trial data demonstrating that pharmaceutical reduction of triglycerides significantly reduces residual cardiovascular risk.
If you wish to serve as lead plaintiff, you must move the Court no later than January 3, 2014. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, or to discuss your rights or interests regarding this class action, please contact Thomas J. McKenna, Esq. or Gregory M. Egleston, Esq. of Gainey McKenna & Egleston at (212) 983-1300, or via e-mail at email@example.com or firstname.lastname@example.org.
Attorney Advertising -- Prior results do not guarantee a similar outcome with respect to any future matter. Please visit our website at http://www.gme-law.com for more information about the firm.